REVIEW Thalidomide is used for treating multiple myeloma in combination with dexamethasone, erythema nodosum leprosum, and alleviating symptoms of HIV, with strict controls to prevent birth defects. Thalidomide is a potent inhibitor of new blood vessel growth (angiogenesis), which is required for tumor growth.
REFERENCES
[1]
Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA (2012). A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 118(16):3968-76. PMID 22180010.
[2]
Horton MR, Hallowell RW (2012). Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today (Barc). 48(10):661-71. PMID 23110262.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.
WARNING: Attention California residents: This product can expose you to chemicals including (+/-)-Thalidomide, which is known to the State of California to cause birth defects or other reproductive harm. For more information, go to www.P65Warnings.ca.gov.